The presence of concomitant mutations may affect the response to targeted therapies, and this was confirmed in the case of EGFR tyrosine kinase inhibitors (EGFR-TKI) in NSCLC, where EGFR-mutant tumors also presented mutations in other genes (e.g., KRAS, BRAF, NRAS, MET), which were previously classified as mutually exclusive [18,19]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.